Bipartisan legislation, S. 1333, is pending in the Senate to amend the Controlled Substances Act to exclude cannabidiol and cannabidiol-rich plants from the definition of marijuana.
Cannabidiol is a non-psychotropic compound in the plant that possesses various therapeutic properties, including anti-convulsant activity. Clinical trials have determined it to be safe and well tolerated in human subjects.
To date, 15 states have enacted laws exempting CBD from the definition of marijuana. However, patients in these states still lack access to CBD because it is classified as a schedule I controlled substance under federal law.
S. 1333 is one of six pieces of legislation presently pending before Congress to permit and/or protect patient access to CBD. Other legislation includes:
By entering your zip code below, you can contact your federally elected officials in regard to this pending legislation.
National Organization for the Reform of Marijuana Laws – Advocacy Campaigns
